ACOR - Acorda Therapeutics Inc Stock Price, Fair Value and News

$0.26-0.02 (-7.14%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ACOR Price Action

Last 7 days

-25%

Last 30 days

-61.5%

Last 90 days

-97.6%

Trailing 12 Months

-97.2%

ACOR RSI Chart

ACOR Valuation

Market Cap

322.9K

Price/Earnings (Trailing)

Price/Sales (Trailing)

EV/EBITDA

0.04

Price/Free Cashflow

-0.01

ACOR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ACOR Fundamentals

ACOR Revenue

Revenue (TTM)

115.7M

Rev. Growth (Yr)

-8.85%

Rev. Growth (Qtr)

-46.59%

ACOR Earnings

Earnings (TTM)

-263.4M

Earnings Growth (Yr)

-62.83%

Earnings Growth (Qtr)

87.42%

ACOR Profitability

EBT Margin

-263.21%

Return on Equity

-446.81%

Return on Assets

-322.92%

Free Cashflow Yield

-8.5K%

ACOR Investor Care

Shares Dilution (1Y)

2.07%

Diluted EPS (TTM)

-212.09

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	115.7M	0	0	0
2023	118.3M	116.9M	111.1M	117.6M
2022	122.7M	122.0M	124.1M	118.6M
2021	153.7M	151.9M	130.3M	129.1M
2020	176.4M	159.9M	165.3M	153.0M
2019	409.4M	306.2M	211.1M	192.4M
2018	575.1M	588.9M	590.7M	471.4M
2017	523.1M	535.1M	540.5M	588.3M
2016	508.7M	522.5M	509.9M	519.6M
2015	420.8M	437.4M	479.6M	492.7M
2014	345.1M	355.2M	376.2M	401.5M
2013	306.4M	317.8M	325.3M	336.4M
2012	302.2M	312.6M	297.0M	305.8M
2011	235.1M	256.9M	286.3M	292.2M
2010	57.3M	86.0M	135.2M	191.1M
2009	0	53.8M	54.2M	54.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

CEO	Dr. Ron Cohen M.D.
WEBSITE	acorda.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	111

Acorda Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Acorda Therapeutics Inc? What does ACOR stand for in stocks?

ACOR is the stock ticker symbol of Acorda Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acorda Therapeutics Inc (ACOR)?

As of Thu Jun 13 2024, market cap of Acorda Therapeutics Inc is 322.94 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACOR stock?

You can check ACOR's fair value in chart for subscribers.

Is Acorda Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACOR is over valued or under valued. Whether Acorda Therapeutics Inc is cheap or expensive depends on the assumptions which impact Acorda Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACOR.

What is Acorda Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, ACOR's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACOR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Acorda Therapeutics Inc's stock?

In the past 10 years, Acorda Therapeutics Inc has provided -0.614 (multiply by 100 for percentage) rate of return.